Pig Welfare: Immunocastration
We are exploring opportunities to increase the adoption of immunocastration as a higher-welfare alternative to surgical castration in pigs.
The welfare problem
Male pigs raised for meat are commonly castrated to prevent boar taint — an off-odor and off-flavor in cooked meat caused mainly by two compounds, androstenone and skatole, that accumulate in entire (uncastrated) males as they reach sexual maturity. To avoid taint and manage male behavior, much of the industry castrates piglets surgically, frequently in the first days of life and, in many regions, without anesthesia or post-operative pain relief.
Surgical castration is acutely painful and carries risks of infection, hemorrhage, and impaired growth. It is one of the most widespread routine welfare insults in pig production, affecting a very large number of animals every year.
What immunocastration is
Immunocastration is a vaccine-based alternative. Rather than removing the testes surgically, the animal receives a vaccine — administered in two doses, with the second given some weeks before slaughter — that stimulates the pig's own immune system to temporarily suppress testicular function. This lowers the hormones responsible for boar taint, achieving the same end (taint-free meat) without the pain of surgery.
Immunocastration at a glance
- Mechanism
- A vaccine that prompts the pig's immune system to suppress the production of taint-causing compounds.
- Doses
- Typically two injections, with the second administered weeks before slaughter.
- Welfare benefit
- Avoids the acute pain, stress, and infection risk of surgical castration.
- Regulatory status
- Licensed and used in a number of markets worldwide, including under the brand most commonly known as Improvac / Improvest.
- Co-benefits
- Entire and immunocastrated males convert feed more efficiently and produce leaner carcasses than surgically castrated males.
Why adoption lags behind the science
The technology works and is approved in many places — yet uptake remains limited and uneven. The obstacles are rarely about whether immunocastration can be done; they are about coordination, perception, and commercial risk:
- Processor and buyer protocols. Packers and retailers need confidence that taint is reliably controlled, plus clear handling and verification standards along the supply chain.
- Producer familiarity and logistics. A two-dose vaccination schedule changes farm workflow and requires training, timing discipline, and trust in the outcome.
- Worker perceptions. Concerns about accidental self-injection are addressable with safety devices and training, but they shape attitudes.
- Market and consumer messaging. The word "vaccine" and the word "castration" both invite misunderstanding; clear, accurate communication matters.
- Trade and standards alignment. Export markets and assurance schemes do not always treat the method consistently.
What we are doing
Our work on pig welfare is aimed at understanding these barriers and identifying realistic pathways for implementation. It includes:
- Research. Synthesizing the evidence on welfare, meat quality, economics, and existing adoption — and mapping where immunocastration is already working and why.
- Stakeholder engagement. Talking with producers, processors, veterinarians, researchers, and welfare organizations to learn what would actually move adoption in a given market.
- Educational efforts. Helping the people involved in these decisions access clear, accurate information about how immunocastration works and what it requires.
For pigs, our goal is not to invent a new solution, but to help an existing higher-welfare one reach the animals that could benefit from it.
Get involved
If you are a producer, processor, researcher, veterinarian, or funder with a perspective on immunocastration — or you are working on the same problem — we would value the conversation. Get in touch.